NASHVILLE, Tenn., March 17/PRNewswire/ -- Brad Tice, Pharm.D., chief clinical officer of PharmMD, will be named a fellow of the American Pharmacists Association (APhA) at its upcoming annual meeting, scheduled for March 14-17 in San Diego, Calif.
Among his many career accomplishments, Dr. Tice helped make medication therapy management (MTM) what it is today. MTM refers to the process of preventing drug error, overuse and abuse by ensuring that individual patients receive the most appropriate medications possible. Dr. Tice was a member of the team that wrote the accepted clinical definition of MTM approved by 11 organizations including the APhA. He also participated on the advisory panel that developed the MTM model jointly issued by APhA and NACDS. As evidence of the increasing value and importance of MTM, the Centers for Medicare and Medicaid Services (CMS) began in 2006 requiring each sponsor of its Part D drug benefits to incorporate an MTM program into their plan's benefit structure. CMS leadership has referred to MTM as the "cornerstone" of the Part D Medicare benefit.
Dr. Tice currently serves as chief clinical officer for PharmMD, an MTM provider that works with employers, government plans and other payers to help ensure that beneficiaries are receiving the most appropriate medications by improving coordination and communication among physicians, pharmacists, payers and patients. The company analyzes medical and pharmaceutical utilization records to prevent harmful drug interactions and costly duplications. After only one quarter of providing MTM services to approximately 3,000 covered lives at a large, self-insured employer, PharmMD reported $3 saved for ever $1 spent on its services.
"As our company's clinical leader, Dr. Tice's services have likely saved several lives and improved many more," said Bo Bartholomew, founder and CEO of PharmMD. "He is a pioneer in his industry and a critical member of our executive team."
Copyright©2008 PR Newswire.
All rights reserved